Expert Insights on Gene Therapy for International Batten Awareness Day
Neuronal ceroid lipofuscinosis (NCL) is a group of 13 rare inherited lysosomal disorders affecting the ne...
Theranexus and BBDF granted positive opinion by EMA for the design of Phase III trial to evaluate Batten-1 in CLN3 Batten disease
Lyon, France – Austin, Texas, United States – 7 June 2023 – 7.30 am CEST – Theranexus, a biopharmaceutica...
Families raised millions and handed rare disease therapies off to biotechs. But companies have backed out
When Julia Taravella’s two sons were diagnosed with an ultra-rare disease, she did something extraordinar...
Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to evaluate Batten-1 in CLN3 Batten disease
Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to evaluate Batten-1 i...
My son’s time is running out due to a rare disease. The FDA needs to add more clinical trial flexibility
By Judy Stecker Feb. 28, 2023 My toddler, Wheeler, will probably not live to adulthood. Juvenile Batten...
BBDF Presents at World Symposia 19th Annual Scientify Meeting
BBDF was proud to partner with Theranexus and Engaged Health to present Understanding the Functional Burd...
THERANEXUS, BBDF AND CARDIFF UNIVERSITY PRESENT THEIR NOVEL RESEARCH ON BATTEN-1 AND BATTEN DISEASE AT WORLDSYMPOSIUM 2023
From 22 to 26 February 2023 in Orlando, Florida ▪ Presentation of preclinical data demonstrating how Ba...
NCL Congress Report
BBDF sponsored Ineka Whiteman, PhD to attend the 7th Meeting Translational Research Conference for the Ma...
New Advance to the Theranexus and BBDF Batten-1 Program for Juvenile Batten Disease (CLN3)
Beyond Batten Disease Foundation is excited to share the latest accomplishment on our journey to find a t...